Fig. 3
From: HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma
CDK4/6 inhibitors as a putative target for intrahepatic cholangiocarcinoma (iCCA).
A, Representative western blot analysis of Cyclin D1 in hepatobiliary cancer cell lines.
B, Palbociclib drug sensitivity half maximal inhibitory concentration (IC50) values (nM).
C, Western blot analysis of genes involved in the PI3K/Akt pathway and cell cycle-related proteins in iCCA cell lines HUCCT1 and RBE cells treated with palbociclib or with water control. Protein lysates were collected after drug treatment for 48Â h.
D-E, palbociclib inhibited the proliferation, migration and invasion of iCCA cell lines. Cell proliferation was evaluated with CCK − 8 assay. Cell migration and invasion were investigated with transwell assays.
F-G, Western blot analysis of EMT-related factors and cell stemness-related proteins in iCCA cell lines HUCCT1 and RBE cells treated with palbociclib (3000 nM/500 nM), or control. Protein lysates were collected after drug treatment for 48Â h.
H-I, Images showing 3D sphere formation and colony formation assays of iCCA cell lines, after 3000nM (HUCCT1) or 500 nM (RBE) palbociclib treatment for 9 days.
Data were shown as mean ± SEM. n.s. represents not significant. *p < 0.05, **p < 0.01 and ***p < 0.001 as calculated by the one-way or two-way ANOVA. Data from one representative experiment are presented (n = 3)